Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

XBIO vs ACHV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACHV Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–2 Matrix Metrics)

ACHV Overall Winner 6-Pillar Tally: XBIO 2 – 3 ACHV (1 Tie) Matrix Metrics: XBIO 2 – 8 ACHV

As of Nov 16, 2026, Achieve Life Sciences, Inc. (ACHV) is the stronger overall head-to-head candidate over Xenetic Biosciences, Inc. (XBIO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). XBIO carries a Unified Composite Score of 47.1/100 (HOLD) at $1.49 (N/M Forward P/E, -81.0% operating margin), whereas ACHV carries 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: XBIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9); meanwhile ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XBIO vs ACHV
XBIO NASDAQ
Xenetic Biosciences, Inc.
Pharmaceutical Preparations
$1.49
-10.24% 1D
Market Cap $3.9M
TTM Revenue $3.3M
Forward P/E N/M
Beta / 30D Vol 1.60β · 97% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 33.0 Fund 50.0 Flow 50.0 Mom 74.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.8%), weak momentum, RSI 29
RSI-14: 28.9 · SMA20: $1.89 · SMA50: $2.35
ACHV NASDAQ Head-to-Head Winner
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
TTM Revenue N/A
Forward P/E 35.3x
Beta / 30D Vol 1.73β · 62% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.1 · SMA20: $6.72 · SMA50: $7.28

6-Pillar Scorecard Institutional Category Breakdown (XBIO 2 – 3 ACHV)

Columns: Metric · XBIO · ACHV
1. Valuation Multiples ACHV
Forward P/E N/M 35.3x
Trailing P/E N/M 35.3x
PEG Ratio N/M 17.68x
EV / Revenue 1.2x N/M
2. Growth & Scale XBIO
Revenue Growth (YoY) +12.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $3.3M N/A
Market Cap $3.9M $692.8M
3. Profitability & Quality ACHV
Gross Margin 100.0% N/A
Operating Margin -81.0% 0.0%
Net Profit Margin -75.9% 0.0%
Return on Equity (ROE) -47.0% -845.0%
4. Balance Sheet & Cash Flow XBIO
Cash Generation (TTM) -$1.8M -$44M
Cash Flow Margin -55.8% N/A
Net Cash / Leverage $3.23 Book/Sh · -47.0% ROE $46M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACHV
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile N/A (N/A) 88.3% (23rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XBIO (2) vs ACHV (8)
Institutional Metric XBIO ACHV Criterion Row Edge
Market Capitalization
Scale
$3.9M $692.8M Larger Scale ACHV
Trailing P/E Ratio
Valuation
N/M 35.3x Lower Multiple ACHV
Forward P/E Ratio
Valuation
N/M 35.3x Lower Multiple ACHV
Revenue Growth (YoY)
Growth
+12.0% +0.0% Higher Growth XBIO
Operating Margin (TTM)
Profitability
-81.0% 0.0% Higher Margin ACHV
Net Profit Margin
Profitability
-75.9% 0.0% Higher Margin ACHV
Return on Equity (ROE)
Capital Efficiency
-47.0% -845.0% Higher ROE XBIO
52-Week Range Position
Momentum
2% ($1–$5) 69% ($3–$9) Stronger Trend ACHV
Beta / 30D Volatility
Risk Regime
1.60β · 97% Vol 1.73β · 62% Vol Lower Realized Risk ACHV
Unified Institutional Score
Composite Signal
47.1 / 100 (HOLD) 56.6 / 100 (HOLD) Higher Composite ACHV
Trailing 12M Revenue (USD)
Operating Scale
$3.3M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.2x EV/Rev 17.68x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.8M ($3.23 Book/Sh · -47.0% ROE) -$44M ($46M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACHV +7.11 pp
XBIO: -15.61% · ACHV: -8.5%
3M Horizon ACHV +44.33 pp
XBIO: -44.18% · ACHV: +0.15%
6M Horizon ACHV +64.04 pp
XBIO: -42.75% · ACHV: +21.29%
1Y Horizon ACHV +78.09 pp
XBIO: -30.06% · ACHV: +48.03%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XBIO vs ACHV. Trailing 12-month operating profitability (XBIO -81.0% vs ACHV 0.0%) and valuation multiples (XBIO N/M vs ACHV 35.3x Forward P/E) are benchmarked directly in Pillar 4 below.

XBIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.3M
Gross Margin100.0%
Op. Margin-81.0%
ROE / Fwd P/E-47.0% · N/M
ACHV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-845.0% · 35.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XBIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACHV BREAKOUT
125d in phase · OBV NEUTRAL
Current IV 88.3%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ACHV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.9M market capitalization and -81.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACHV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $692.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XBIO vs ACHV Key Questions & Quantitative Answers

As of Nov 16, 2026, Achieve Life Sciences, Inc. (ACHV) is the stronger overall head-to-head candidate over Xenetic Biosciences, Inc. (XBIO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). XBIO carries a Unified Composite Score of 47.1/100 (HOLD) at $1.49 (N/M Forward P/E, -81.0% operating margin), whereas ACHV carries 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: XBIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9); meanwhile ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

XBIO leads the Growth & Scale pillar: XBIO posts +12.0% YoY revenue growth and +0.0% YoY earnings growth on $3.3M TTM revenue (100.0% gross margin, -81.0% operating margin), compared with ACHV at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, XBIO generates $3.3M in USD-normalized revenue versus N/A for ACHV. In operating R&D and SG&A reinvestment, XBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACHV.

ACHV screens cheaper on headline valuation multiples. XBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.2x EV/Revenue (-55.8% FCF margin), whereas ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XBIO (-47.0% ROE) versus ACHV (-845.0% ROE) capital efficiency.

In options market volatility and institutional positioning, XBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.60β · 97% Vol realized risk). By comparison, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.